C.jpg c_ph.jpg
Pipeline
Ophthalmology

We aim to develop innovative disease-modifying therapeutics to preserve and improve patients’ vision.  The strength of our ophthalmology pipeline derives from our strong clinical development capability and close collaboration with industry and academic partners coupled with our deep scientific knowledge of diseases affecting the eye. 

With a diverse portfolio of drugs and drug candidates at different stages of development, we are focused on bringing patients safe and effective, best-in-class therapeutics for a spectrum of ophthalmic diseases in both the front and the back of the eye. The ophthalmic disease states we are targeting all are underserved clinically, with significant unmet medical needs in Greater China and other Asian countries.

Program Lead Indication AffaMed Territory Pre-clinical/IND Phase I Phase II Phase III Approved
AM007
DEXTENZA

Detail

Post surgical pain/infl, AC Greater China, Korea, SEA
AM008
OTX-TIC

Detail

Glaucoma Greater China, Korea, SEA
IOLs

Detail

Cataract Greater China
AM305
AG-73305

Detail

DME, nAMD, RVO Greater China, South Korea & SEA
AM011
Luminate

Detail

Dry AMD Greater China
AM712
ASKG712

Detail

nAMD, DME Global (excl. Asia & Japan)
AM002
SB11/Ranibizumab

Detail

wAMD, DME, RVO Mainland China, Singapore
AM003
SB15/Aflibercept

Detail

wAMD, DME Mainland China, Singapore
AM007
DEXTENZA

Read More

Lead Indication
Post surgical pain/infl, AC
AffaMed Territory
Greater China, Korea, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
AM008
OTX-TIC

Read More

Lead Indication
Glaucoma
AffaMed Territory
Greater China, Korea, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
IOLs

Read More

Lead Indication
Cataract
AffaMed Territory
Greater China
Pre-clinical/IND Phase I Phase II Phase III Approved
AM305
AG-73305

Read More

Lead Indication
DME, nAMD, RVO
AffaMed Territory
Greater China, South Korea & SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
AM011
Luminate

Read More

Lead Indication
Dry AMD
AffaMed Territory
Greater China
Pre-clinical/IND Phase I Phase II Phase III Approved
AM712
ASKG712

Read More

Lead Indication
nAMD, DME
AffaMed Territory
Global (excl. Asia & Japan)
Pre-clinical/IND Phase I Phase II Phase III Approved
AM002
SB11/Ranibizumab

Read More

Lead Indication
wAMD, DME, RVO
AffaMed Territory
Mainland China, Singapore
Pre-clinical/IND Phase I Phase II Phase III Approved
AM003
SB15/Aflibercept

Read More

Lead Indication
wAMD, DME
AffaMed Territory
Mainland China, Singapore
Pre-clinical/IND Phase I Phase II Phase III Approved
Program:
Partner: